This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Blackwell, N. Articles by Trotman, I. Search for Related Content PubMed PubMed Citation Articles by Blackwell, N. Articles by Trotman, I. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Cancer Pain Hazardous Substances DB TOLMETIN Social Bookmarking                   What's this?

Subcutaneous ketorolac- a new development in pain control

Michael Sobell House, Mount Vernon Hospital, Northwood, Middlesex

L. Bangham

Michael Sobell House, Mount Vernon Hospital, Northwood, Middlesex

M. Hughes

Michael Sobell House, Mount Vernon Hospital, Northwood, Middlesex

D. Melzack

Michael Sobell House, Mount Vernon Hospital, Northwood, Middlesex

I. Trotman

Michael Sobell House, Mount Vernon Hospital, Northwood, Middlesex

Pain due to advanced malignant disease does not always respond to opioids, or the possible use of opioids may be limited by the occurrence of adverse effects. This paper describes the successful use of ketorolac, a new nonsteroidal anti-inflammatory drug, given by continuous subcutaneous infusion. Seven patients with pain due to advanced malignant disease taking opioid analgesia were considered to have inadequate symptom control because of opioid unresponsiveness (n = 1 ), opioid-related adverse effects (n = 2) or both (n = 4). All patients became symptom-free with the introduction of ketorolac by subcutaneous infusion and the total daily opioid requirement was substantially reduced in three and reduced to zero in four patients.

Key Words: Ketorolac • anti-inflammatory agents • nonsteroidal • narcotics • palliative treatment

Palliative Medicine, Vol. 7, No. 1, 63-65 (1993)
DOI: 10.1177/026921639300700110


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C. A Jenkins and E. Bruera Nonsteroidal anti-inflammatory drugs as adjuvant analgesics in cancer patients Palliative Medicine, April 1, 1999; 13(3): 183 - 196. [Abstract] [PDF]

				S. H Drummond, G. M Peterson, J. G Galloway, and P. A Keefe National survey of drug use in palliative care Palliative Medicine, April 1, 1996; 10(2): 119 - 124. [Abstract] [PDF]

				V. Pace Use of nonsteroidal anti-inflammatory drugs in cancer Palliative Medicine, October 1, 1995; 9(4): 273 - 286. [Abstract] [PDF]

				A. R Duncan and L. Davis Subcutaneous ketorolac Palliative Medicine, January 1, 1995; 9(1): 77 - 78. [PDF]

				Subcutaneous infusions - a medical last rite Palliative Medicine, April 1, 1994; 8(2): 91 - 93. [PDF]

				P. Maguire, A. Faulkner, and C. Regnard Handling the withdrawn patient- a flow diagram Palliative Medicine, October 1, 1993; 7(4): 333 - 338. [Abstract] [PDF]

				P. Maguire, A. Faulkner, and C. Regnard Managing the anxious patient with advancing disease- a flow diagram Palliative Medicine, July 1, 1993; 7(3): 239 - 244. [Abstract] [PDF]